Biotechnology Companies in the News – November 2011

Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via email.

November 10
Merck Executing on Strategy to Position Company for Long-Term Sustainable Growth

Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing

November 9
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference

Unigene Reports Third Quarter 2011 Financial Results

Unigene Announces Positive Top-Line Results Of Phase 2 Oral Pth Study For The Treatment Of Osteoporosis In Postmenopausal Women

BioReference Laboratories, Inc. to Speak at the Lazard Capital Markets 8th Annual Healthcare Conference

CircuLite® to Present at Lazard Capital Markets Healthcare Conference

Merck Launches NEXPLANON® (etonogestrel implant) 68 mg in the United States – A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years

November 8
BioNeutral Group Signs Definitive Agreements to Improve Balance Sheet by $6.8 Million and Lower Debt to Nearly Zero

Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-1127

12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb’s NS5A Inhibitor Daclatasvir Support Anti-HCV Activity and Safety Profile Observed in Earlier Studies

Outstanding Interim Results of STENTYS International Clinical Study of 600 Heart Attack Patients

Antares Pharma Reports Third Quarter 2011 Financial and Operating Results

Flexible Stenting Solutions, Inc. Announces First Implant of the 200 mm FlexStent® Femoropopliteal Self Expanding Stent System

Oceana Therapeutics Announces Definitive Agreement to Be Acquired by Salix Pharmaceuticals

Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms

Pharmasset to Present at Credit Suisse First Boston Healthcare Conference

First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT

Phase II Study Evaluating Apremilast as an Oral Treatment for Patients with Ankylosing Spondylitis Presented at ACR

November 7
NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism

FDA Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil

All-Oral Treatment Regimen of Bristol-Myers Squibb’s Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virologic Response (SVR12) in Phase II Study Sentinel Cohort of Genotype 1b Null Responders

PTC Therapeutics Receives Grand Challenges Explorations Funding

November 4
NPS Pharmaceuticals Announces NASDAQ Opening Bell Ceremony

Pharmasset to Webcast an Investor Event from the AASLD Meeting

November 3
Columbia Laboratories Reports Third Quarter 2011 Financial Results

BioNeutral Group Appoints New Board of Directors and Expands Management Team

ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership to License and Develop Investigational Oncology Compound

New Investigational Data on ORENCIA® (abatacept) to Be Presented at the American College of Rheumatology Annual Scientific Meeting

NPS Pharmaceuticals Reports Third Quarter 2011 Financial Results and Improves Cash Burn Guidance

Senesco Initiates Dosing in Phase 1b/2a Clinical Study of SNS01-T

Enzon Reports 3rd Quarter 2011 Results

Celgene Corporation to Present at the Credit Suisse 2011 Healthcare Conference

November 2
Celldex Reports Third Quarter 2011 Financial Results

The Medicines Company Announces Schedule of Events at Upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference

November 1
NovaDel Reports Financial Results for Third Quarter 2011

MedAvante Is One Of NJ’s Fastest Growing Companies

Amicus Therapeutics Announces Third Quarter 2011 Financial Results

Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV

October 31
Phase 3 GATTEX(R) (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome

NPS Pharmaceuticals to Host Conference Call to Discuss Data Reported at American College of Gastroenterology Annual Scientific Meeting

Celldex Therapeutics Announces Orphan Drug Designation in the European Union for Rindopepimut, a Novel EGFRvIII Vaccine for Glioblastoma

Merck Announces Dates for R&D and Business Briefing and Fourth-Quarter 2011 Sales and Earnings Report

October 28
Merck Announces Third Quarter 2011 Financial Results

Advaxis Receives Additional Financing

For Immediate Release to US Investors: The Medicines Company and Daiichi Sankyo Announce Angiox(R) (Bivalirudin) Co-Promotion for Germany

October 27
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development

Columbia Laboratories to Discuss Third Quarter 2011 Financial Results on November 3, 2011, Conference Call

Celgene Reports Record Third Quarter 2011 Operating and Financial Results

SwabCap Is Focus of NACHRI Pediatric Conference Award

GenPath Women’s Health in Collaboration with GeneDX to Launch Breakthrough in Genetic Screening for Family Planning

NPS Pharmaceuticals to Report Third Quarter 2011 Financial Results

October 26
Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV

GE Healthcare Presents at TEDMED Conference on Importance of Molecular Diagnostics in Personalized Treatment Paradigm

Senesco Technologies Provides Corporate Update

U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months

New Approaches from Regional Researchers Recognized at Biotech 2011 Innovation Corridor

New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males

The Medicines Company Reports Third Quarter 2011 Results

October 25
Pop Test Cortisol Acquires Chemotherapy Sensitizer Org34517 from Merck & Co.

Paragon Co-Chairs Second CBI Conference on Electronic Trial Master File Implementation

CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men

University of Michigan Oncologist Receives Breast Cancer Research Foundation Grant for Work with Tumor Markers

BioReference’s Genetic-Testing Business Has New Tool for Detecting Rare Diseases

Celldex Therapeutics to Participate on Business Development Panel at BIO-Europe® 2011 in Duesseldorf, Germany

October 24
ViroStatics CEO, Dr. Franco Lori, to Speak at the International Track During Pennsylvania Biotech 2011

Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing At Commercial Scale

October 21
Data from Phase 2 Clinical Studies of Telotristat Etiprate in Patients with Carcinoid Syndrome to Be Presented at North American Neuroendocrine Tumor Society Meeting

October 20
Cardiac Device Infections Cost Money and Lives

Unigene Completes All Patient Dosing in Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women

Unigene to Present at the 10th Annual BIO Investor Forum on October 25, 2011

Senesco Technologies to Present at BIO Investor Forum Conference

October 19
NCPDP and SAFE-BioPharma to Collaborate on Life Science Standards

Columbia Laboratories Recognized on the Deloitte Technology Fast 500

Amicus Therapeutics Announces Close of Patient Recruitment in First Phase 3 Study of Amigal(TM) for Fabry Disease

Bristol-Myers Squibb Announces Changes in Senior Management Team

Bristol-Myers Squibb Foundation Awards $2.12 Million in Grants to Help Returning Soldiers Heal Emotional Wounds of War

October 18
Dr. Roberto Romero, NIH Principal Investigator of PREGNANT Study, Co-Sponsored by Columbia Laboratories, Honored with John Dingell Hero for Babies Award by March of Dimes

Advaxis Announces Notice of Allowance of US Patent for ADXS-HPV Immunotherapy

Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants

Sentrx Enhances Performance Management Metrics

October 17
Advaxis to Present at the 2011 10th Annual BIO Investor Forum on October 25th

Enzon Announces Management Change, Forms Special Committee of the Board

October 15
The Medicines Company’s MDCO-2010 Meets Clinical Trial Objectives in Patients Undergoing Open-Heart Surgery

October 14
Sentrx Announces Resignation of Charles T. Saldarini as CEO